Looking At M&A History, What Metrics Suggest That Pfizer Has Been Conservative While Engineering Allergan Deal?
Pfier & Allergan Merger Deal
- Synergies announced as % of combined sales < healthcare sector median
- Allergan’s fair share of synergies post merger ~ healthcare sector median
- Should You Pick Pfizer Stock At $30 After A 30% Fall In A Year?
- Should You Pick Pfizer Stock At $30?
- Down 25% In A Year Will Pfizer Stock Rebound To Its Pre-Inflation Shock Level?
- Will Pfizer Stock See Higher Levels Post Q1 Earnings?
- Is Pfizer Stock Undervalued At $40?
- This Logistics Company Appears To Be A Better Pick Over Pfizer Stock
Source for Healthcare sector data: How Successful M&A Deals Split the Synergies (complied for M&A activities between 2000 and 2011)
Have more questions about Pfizer? See the links below.
- By What Percentage Can Pfizer’s Revenue & EBITDA Grow In The Next 3 Years?
- By What Percentage Did Pfizer’s Revenue & EBITDA Decline In The Last 5 Years?
- What’s Pfizer’s Revenue And Earnings Breakdown?
- What’s Pfizer’s Fundamental Value Based On Expected 2015 Results?
- What Could Pfizer’s Value Be In 2018?
- How Much Additional Synergies Does Pfizer Require To Justify Premium Paid For Allergan?
- How Much Revenues Can Pfizer’s Phase 3 Pipeline Add By 2020?
- How Has Pfizer’s Revenue Composition Changed Over The Last 5 Years?
- How Important Is Prevnar Vaccine For Pfizer?
Notes:
See More at Trefis | View Interactive Institutional Research (Powered by Trefis)